The subject of gene patentability is one of the most controversial topics in life sciences. In June 2013, the US Supreme Court reached a unanimous decision in the Association for Molecular Pathology v Myriad Genetics. It stated that companies cannot patent parts of naturally occurring human genes. Managing IP sat down with Fitzpatrick Cella Harper & Scinto attorneys Robert Fischer, John Carlin and Joshua Rothman to discuss the ruling
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
Abbott winning another round against Sinocare and Menarini, and 'long arm' clarification on the UK's position within the UPC, were also among major developments
Executive chair Matt Dixon, who reveals a new associate hire, says the firm wants to offer a realistic pathway to partnership while avoiding the ‘corporate machine’ route
Kevin Mack, Via’s new president, emphasises the importance of collaborative licensing structures and shares how AI tools can help create new lines of business